^
Association details:
| Biomarker: | LAMC2 overexpression |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | gemcitabine (DNA synthesis inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
1411 - LAMC2 promotes progression and gemcitabine resistance through modulation of EMT and ATP-binding transporters in pancreatic ductal adenocarcinoma
Published date:
03/10/2021
Excerpt:
Higher expression of LAMC2 significantly correlated with poor survival in PDAC patient cohort (overall survival [OS]: 23.0 vs 14.2 months, Hazard ratio [HR]=1.61; 95% confidence interval [CI], 1.09-2.79, P < 0.01, relapse-free survival [RFS]: 9.0 vs 6.2 months, HR=1.61, 95%CI, 0.96-2.71, P < 0.05)...Moreover, higher LAMC2 expression levels predicted response to gemcitabine-based adjuvant therapy in patients with PDAC (HR=1.66, 95%CI, 0.94-2.93).
